| URL | https://www.businesswire.com/news/home/20230425006 |
| Source | business wire |
| Date Published | 04/26/2023 |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | Bristol Myers Squibb |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2023 |
| Year reshoring implemented or to be implemented: | 2023 |
| Domestically, the work will be done: | In-house |
| City reshored to: | Libertyville |
| State(s) reshored to: | IL |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | CAR T cell therapies |